HER2 positive gastric cancer

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
2 Unique sponsors
9 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 3
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Platinum compound 2 substances
Unknown / small molecule 2 substances
Antibody-drug conjugate (ADC) 1 substance
Antimetabolite 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Taxane 1 substance
Phase III: 2 Phase II: 1 Phase I/II: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    CISPLATIN; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN
    2024-513122-27-00 12 countries 2025 n=214
    Recruiting

Phase II

1 trial
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    DISODIUM FOLINATE; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZUMAB
    2024-513610-34-00 1 country 2023 n=30
    Ended

Phase I/II

1 trial
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    CALCIUM FOLINATE PENTAHYDRATE; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB DERUXTECAN
    2024-518841-12-00 2 countries 2025 n=39
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 2 Phase III 2
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 2 Phase II, Phase I/II 0
New trials by year
2023
1
2024
1
2025
2
← All indication landscapes